Granite Bio
Phase 1Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $19.2M
About
Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
AntibodiesBiologics
Funding History
2Total raised:$19.2M
Series A$15MMar 15, 2023
Seed$4.2MSep 15, 2021